Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Burger

Showing results (901-910 of 1,155) with videos related to

Pageof 116
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemiaWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.
Leukemia Research|September 10, 2020
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemiaIsabelle G Solman, Lisa K Blum, Hana Y Hoh, et al.
European Radiology|March 9, 2023
Combined forced diuresis and late acquisition on [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented studyMatteo Bauckneht, Alberto Miceli, Alessio Signori, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group StudyRobert A Burger, Mark F Brady, Michael A Bookman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian CancerLarissa A Meyer, Angel M Cronin, Charlotte C Sun, et al.
Leukemia|May 18, 2018
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategiesPhilip A Thompson, Christine B Peterson, Paolo Strati, et al.
Medrxiv : the Preprint Server for Health Sciences|August 4, 2022
Health impacts of COVID-19 disruptions to primary cervical screening by time since last screen: A model-based analysis for current and future disruptionsEmily A Burger, Inge M C M de Kok, James F O'Mahony, et al.
Haematologica|November 8, 2011
Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevancePreetesh Jain, Mohammad Javdan, Franziska K Feger, et al.
Plos One|August 4, 2011
Genome-wide association scan in HIV-1-infected individuals identifying variants influencing disease courseDaniëlle van Manen, Olivier Delaneau, Neeltje A Kootstra, et al.
Gynecologic Oncology|December 3, 2021
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group studyNefertiti C duPont, Danielle Enserro, Mark F Brady, et al.
Pageof 116

Showing results (901-910 of 1,155) with videos related to

Sort By:
Pageof 116
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemiaWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.
Leukemia Research|September 10, 2020
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemiaIsabelle G Solman, Lisa K Blum, Hana Y Hoh, et al.
European Radiology|March 9, 2023
Combined forced diuresis and late acquisition on [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented studyMatteo Bauckneht, Alberto Miceli, Alessio Signori, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group StudyRobert A Burger, Mark F Brady, Michael A Bookman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2016
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian CancerLarissa A Meyer, Angel M Cronin, Charlotte C Sun, et al.
Leukemia|May 18, 2018
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategiesPhilip A Thompson, Christine B Peterson, Paolo Strati, et al.
Medrxiv : the Preprint Server for Health Sciences|August 4, 2022
Health impacts of COVID-19 disruptions to primary cervical screening by time since last screen: A model-based analysis for current and future disruptionsEmily A Burger, Inge M C M de Kok, James F O'Mahony, et al.
Haematologica|November 8, 2011
Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevancePreetesh Jain, Mohammad Javdan, Franziska K Feger, et al.
Plos One|August 4, 2011
Genome-wide association scan in HIV-1-infected individuals identifying variants influencing disease courseDaniëlle van Manen, Olivier Delaneau, Neeltje A Kootstra, et al.
Gynecologic Oncology|December 3, 2021
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group studyNefertiti C duPont, Danielle Enserro, Mark F Brady, et al.
Pageof 116